Analysts Set Caribou Biosciences, Inc. (NASDAQ:CRBU) PT at $10.33

Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) have received a consensus rating of “Buy” from the five brokerages that are presently covering the firm, Marketbeat reports. Five research analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $10.33.

Several equities analysts recently weighed in on CRBU shares. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Caribou Biosciences in a report on Wednesday, March 19th. Bank of America dropped their target price on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th.

Hedge Funds Weigh In On Caribou Biosciences

A number of institutional investors have recently made changes to their positions in the business. Ancora Advisors LLC raised its stake in shares of Caribou Biosciences by 16.0% in the 4th quarter. Ancora Advisors LLC now owns 58,000 shares of the company’s stock valued at $92,000 after purchasing an additional 8,000 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Caribou Biosciences by 28.8% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 35,848 shares of the company’s stock valued at $57,000 after buying an additional 8,008 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in Caribou Biosciences by 4.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 176,654 shares of the company’s stock valued at $281,000 after buying an additional 8,199 shares in the last quarter. Milestone Asset Management LLC lifted its holdings in Caribou Biosciences by 5.6% during the 4th quarter. Milestone Asset Management LLC now owns 163,789 shares of the company’s stock worth $260,000 after buying an additional 8,662 shares during the last quarter. Finally, MetLife Investment Management LLC grew its position in shares of Caribou Biosciences by 60.0% in the 4th quarter. MetLife Investment Management LLC now owns 24,404 shares of the company’s stock worth $39,000 after acquiring an additional 9,148 shares in the last quarter. 77.51% of the stock is owned by institutional investors and hedge funds.

Caribou Biosciences Price Performance

Caribou Biosciences stock opened at $0.99 on Friday. The company has a market cap of $91.95 million, a price-to-earnings ratio of -0.60 and a beta of 2.34. Caribou Biosciences has a 12 month low of $0.88 and a 12 month high of $5.23. The stock’s 50-day moving average is $1.25 and its 200-day moving average is $1.71.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Monday, March 10th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.01. Caribou Biosciences had a negative net margin of 1,290.81% and a negative return on equity of 45.46%. The firm had revenue of $2.08 million for the quarter, compared to analyst estimates of $2.11 million. Research analysts anticipate that Caribou Biosciences will post -1.64 EPS for the current year.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.